首页> 外文OA文献 >Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

【2h】

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

机译：Olaparib单疗法作为未选择的三重阴性乳腺癌的主要治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
H.P. Eikesdal; S. Yndestad; A. Elzawahry; A. Llop-Guevara; B. Gilje; E.S. Blix; H. Espelid; S. Lundgren; J. Geisler; G. Vagstad; A. Venizelos; L. Minsaas; B. Leirvaag; E.G. Gudlaugsson; O.K. Vintermyr; H.S. Aase; T. Aas; J. Balmaña; V. Serra; E.A.M. Janssen; S. Knappskog; P.E. Lønning;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1 - or BRCA2 -mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial [J] . Philip C. Schouten, Gwen M. H. E. Dackus, Serena Marchetti, Trials . 2016,第1期

机译：I期，然后是随机的II期临床试验，该试验为两个周期的卡铂-奥拉帕尼联合奥拉帕尼单药治疗与卡培他滨联合治疗BRCA1或BRCA2突变的HER2阴性晚期乳腺癌作为一线治疗（REVIVAL）：一项随机对照试验的研究方案
2. y Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy [J] . Progress in Artificial Intelligence . 2020,第1期

机译：Y低剂量和长期olaparib治疗敏感MDA-MB-231和SUM1315三阴性乳腺癌球体以分配放射疗法
3. Comparative antiproliferative efects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines [J] . PierceA., McgowanP.M., CotterM., Cancer biology & therapy . 2013,第6期

机译：依那普利和奥拉帕尼在一组三阴性和非三阴性乳腺癌细胞系中的比较抗增殖作用
4. Acoustic Cluster Therapy displays theranostic capability in enhancing the effectiveness of liposomal doxorubicin treatment of human triple negative breast cancer in mice [C] . Nigel Bush, Andrew Healey, Anant Shah, IEEE International Ultrasonics Symposium . 2019

机译：声学聚类疗法在提高小鼠中提高人类三重阴性乳腺癌的脂质体Doxorubicin治疗的有效性方面的治疗能力
5. Drug Delivery Strategies for Treatment of Triple Negative Breast Cancer, Ocular Diseases and Biofabrication of Invitro Models [D] . Kutlehria, Shallu. 2020

机译：用于治疗三重阴性乳腺癌，眼部疾病和invitro模型生物制剂的药物递送策略
6. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial [O] . Philip C. Schouten, Gwen M. H. E. Dackus, Serena Marchetti, 2016

机译：I期然后是随机的II期临床试验该试验为两个周期的卡铂-奥拉帕尼联合奥拉帕尼单药治疗与卡培他滨联合治疗BRCA1或BRCA2突变的HER2阴性晚期乳腺癌作为一线治疗（REVIVAL）：一项随机对照试验的研究方案
7. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in - or -mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial [O] . 2016

机译：I期，然后是两个周期的卡铂-olaparib联合olaparib单药疗法与卡培他滨联合HER2阴性或突变的HER2阴性晚期乳腺癌作为一线治疗（REVIVAL）的随机II期试验：一项随机对照试验的研究方案

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅